Zhang Jianbin, Lin Shuangzhe, Jiang Daixi, Li Mengting, Chen Yuanwen, Li Jun, Fan Jiangao
Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Gastroenterology, Yinzhou People's Hospital, Zhejiang, China.
Liver Int. 2020 Mar;40(3):496-508. doi: 10.1111/liv.14369. Epub 2020 Jan 13.
Despite the widespread use of vaccines and antiviral drugs, approximately 350-400 million patients with chronic hepatitis B (CHB) remain worldwide, who carry high risk of cirrhosis and liver carcinoma. Moreover, owing to improvements in global living standards and lifestyle changes, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease. Coexistence of NAFLD and CHB is commonly observed, especially in Asian CHB populations; however, little is known regarding the relationship between these two diseases as comorbidities. In this review, we summarize recent advances in clinical and basic researches related to the underlying mutual interactions, as well as potential animal models to facilitate further investigation.
尽管疫苗和抗病毒药物已广泛使用，但全球仍有大约3.5亿至4亿慢性乙型肝炎（CHB）患者，他们面临着肝硬化和肝癌的高风险。此外，由于全球生活水平的提高和生活方式的改变，非酒精性脂肪性肝病（NAFLD）已成为最常见的慢性肝病。NAFLD与CHB共存的情况很常见，尤其是在亚洲CHB人群中；然而，对于这两种疾病作为合并症之间的关系却知之甚少。在本综述中，我们总结了与潜在相互作用相关的临床和基础研究的最新进展，以及有助于进一步研究的潜在动物模型。
Zotero 插件